Understand the source comparison
Do Peptides Help With Gut Inflammation: Research vs Clinical Application Comparison
BPC-157 VEGF upregulation, NF-κB inhibition, tight junction repair 200–500 mcg daily (SC/IM); 10 mcg/kg (rectal) Subcutaneous: high; Oral (unprotected): low; Oral (enteric): moderate Phase 2 observational data only. No FDA-approved indication Strongest preclin
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, NF-κB inhibition, tight junction repair
- 200–500 mcg daily (SC/IM); 10 mcg/kg (rectal)
- Subcutaneous: high; Oral (unprotected): low; Oral (enteric): moderate
- Phase 2 observational data only. No FDA-approved indication
- Strongest preclinical evidence for mucosal healing; human data remains limited but promising
- KPV (Lys-Pro-Val)
- NF-κB inhibition (nuclear translocation block)
- 5–20 mg daily (oral, enteric-coated)
- Oral (enteric): moderate to high
- Phase 1 completed; Phase 2 ongoing
- Mechanistically sound; clinical evidence still emerging. Insufficient data for definitive efficacy claims
- Thymosin Alpha-1
- T-regulatory cell modulation, immune tolerance restoration
- 1.6 mg twice weekly (SC)
- Subcutaneous: high
- FDA-approved for hepatitis B/C (off-label for IBD)
- Proven immunomodulatory effects; gut-specific efficacy less documented than systemic immune benefits
- Larazotide Acetate
- Tight junction stabilization (zonulin antagonist)
- 0.5–2 mg three times daily (oral)
- Oral: low (designed for local GI effect)
- Phase 3 trials for celiac disease completed
- Mechanism targets barrier function directly; limited efficacy in published trials. Did not meet primary endpoints